<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7392634/table_6" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 6</label>
  <p>Knowns, uncertainties and unknowns about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as of May 2020</p>
 </caption>
 <thead>
  <tr>
   <td align="left" valign="bottom" rowspan="1" colspan="1" id="0-0-.">Factor</td>
   <td align="left" valign="bottom" rowspan="1" colspan="1" id="0-1-.">Available information</td>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Origin of 
    <br/>SARS-CoV-2 
   </td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>Most probably from bats via intermediate animal hosts to index case. 
       <a rid="R47" ref-type="bibr">47 104</a>
      </p>
     </li>
    </ul>
    <ul list-type="bullet">
     <li class="list-item">
      <p>All subsequent cases resulted from human-to-human transmission.</p>
     </li>
    </ul>
   </td>
  </tr>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Transmission</td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>Mainly through respiratory droplets from infected persons 
       <a rid="R105" ref-type="bibr">105</a>; by hands, after contamination at nose, mouth or eyes; also through air on exposure to sneezing or coughing from an infected person at close distance. 
      </p>
     </li>
     <li class="list-item">
      <p>Through aerosols, while singing/talking loudly in congregations, groups, parties, karaoke, and so on, especially in poorly ventilated spaces. 
       <a rid="R18" ref-type="bibr">18 106</a>
      </p>
     </li>
     <li class="list-item">
      <p>Through fomites. 
       <a rid="R107" ref-type="bibr">107</a>
      </p>
     </li>
     <li class="list-item">
      <p>Possibly via faecal–oral route 
       <a rid="R108" ref-type="bibr">108 109</a>; detection in sewage. 
       <a rid="R110" ref-type="bibr">110–112</a>
      </p>
     </li>
     <li class="list-item">
      <p>Related to peak in upper respiratory tract viral load prior to symptom onset in presymptomatic (paucisymptomatic) persons. 
       <a rid="R106" ref-type="bibr">106 113 114</a>
      </p>
     </li>
     <li class="list-item">
      <p>Transmission dynamics in asymptomatic persons not fully elucidated although viral shedding occurs. 
       <a rid="R115" ref-type="bibr">115</a>
      </p>
     </li>
    </ul>
   </td>
  </tr>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Influence of climate and/or air pollution on transmission</td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>Influence of climate on the capacity of the virus to survive outside human body (in air, in droplets, on surfaces, etc.) and to spread has been speculative.</p>
     </li>
     <li class="list-item">
      <p>May spread more readily in milder/colder climate 
       <a rid="R116" ref-type="bibr">116 117</a>; although variability of the reproductive number could not be explained by temperature or humidity. 
       <a rid="R118" ref-type="bibr">118</a>
      </p>
     </li>
     <li class="list-item">
      <p>Existing levels of air pollution may play a role; air pollutants, such as particulate matter, nitrogen dioxide and carbon monoxide, are likely a factor facilitating longevity of virus particles. 
       <a rid="R119" ref-type="bibr">119</a>
      </p>
     </li>
     <li class="list-item">
      <p>Elevated exposure to common particulate matter can alter host immunity to respiratory viral infections. 
       <a rid="R119" ref-type="bibr">119</a>
      </p>
     </li>
    </ul>
   </td>
  </tr>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Immunity—protective antibodies</td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>IgM and IgA antibody response 5–10 days after onset of symptoms, does not depend on clinical severity, correlates with virus neutralisation; IgG is observed ~14 days after onset of symptoms, 
       <a rid="R93" ref-type="bibr">93 120</a> may or may not correspond to protective immunity. Whether antibody response is long lasting has remained unclear. 
      </p>
     </li>
     <li class="list-item">
      <p>Rechallenge in rhesus macaques showed immunity post primary infection. 
       <a rid="R121" ref-type="bibr">121</a> How protective immunity after first infection is against subsequent infection with an identical or mutated strain has been uncertain. 
      </p>
     </li>
     <li class="list-item">
      <p>Incidental reports showed recovered persons positive by real-time PCR, 
       <a rid="R122" ref-type="bibr">122 123</a> later attributed to testing errors. 
      </p>
     </li>
    </ul>
   </td>
  </tr>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Seroprevalence to SARS-CoV-2</td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>Reported estimates for seroprevalence range between 0.4% and 59.3% 
       <a rid="R124" ref-type="bibr">124</a>; differences in timing of the serosurvey, the use of assay kits with varying sensitivity/specificity, and different methods for detection may contribute to this large variation. 
       <a rid="R125" ref-type="bibr">125</a>
      </p>
     </li>
     <li class="list-item">
      <p>Seemingly high seroprevalence may be due to cross-reactive epitopes between SARS-CoV-2 and other HCoVs. 
       <a rid="R126" ref-type="bibr">126 127</a>
      </p>
     </li>
     <li class="list-item">
      <p>Whether seroprevalence implies immune protection is unclear, yet, some countries have considered use of ‘immunity passports’. 
       <a rid="R128" ref-type="bibr">128</a>
      </p>
     </li>
     <li class="list-item">
      <p>For herd immunity to be effectively achieved, an estimated seroprevalence of 60% of the population will be required. 
       <a rid="R37" ref-type="bibr">37</a> Other studies estimate between 5.66% and 85% seroprevalence in different countries. 
       <a rid="R129" ref-type="bibr">129–131</a>
      </p>
     </li>
    </ul>
   </td>
  </tr>
  <tr>
   <td align="left" valign="top" rowspan="1" colspan="1">Rate of variability/mutation in SARS-CoV-2</td>
   <td align="left" valign="top" rowspan="1" colspan="1">
    <ul list-type="bullet">
     <li class="list-item">
      <p>Mutation rate: ~10 
       <sup>−3</sup> substitutions per year per site 
       <a rid="R132" ref-type="bibr">132 133</a>; 13 mutation sites have been identified as of May 2020, suggesting selective mutations. 
       <a rid="R134" ref-type="bibr">134</a>
      </p>
     </li>
     <li class="list-item">
      <p>The low mutation rate suggests that a vaccine would be a single vaccine rather than a new vaccine every year like the influenza vaccine. 
       <a rid="R135" ref-type="bibr">135</a>
      </p>
     </li>
     <li class="list-item">
      <p>Ten different circulating clades ( 
       <div ext-link-type="uri" xlink:href="https://nextstrain.org/" xmlns:xlink="http://www.w3.org/1999/xlink">nextstrain.org</div>; 
       <div ext-link-type="uri" xlink:href="www.gisaid.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.gisaid.org</div>), 
       <a rid="R136" ref-type="bibr">136</a> as of May 2020. 
      </p>
     </li>
    </ul>
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn" id="T6_FN1">
   <p>HCoV, human coronaviruses.</p>
  </p>
 </tfoot>
</table>
